Olema Pharmaceuticals Cleared to Begin Testing Prospective Breast Cancer Candidate-February 2024-www.financetom.com

Olema Pharmaceuticals Cleared to Begin Testing Prospective Breast Cancer Candidate

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Olema Pharmaceuticals Cleared to Begin Testing Prospective Breast Cancer Candidate

Dec 9, 2024 6:57 AM

09:40 AM EST, 12/09/2024 (MT Newswires) -- Olema Pharmaceuticals ( OLMA ) early Monday said the US Food and Drug Administration has cleared the investigational new drug application for the company's OP-3136 drug candidate to treat breast and other types of cancer.

The company is expecting to begin phase 1 testing of OP-3136 early in 2025, Olema said.

Price: 10.51, Change: +0.06, Percent Change: +0.57

Previous page： Market Chatter: Meta to Receive First EU Antitrust Fine Over Marketplace, Facebook Bundling Next page： Update: Pegasystems Shares Rise After Q2 Results Top Estimates

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: Meta to Receive First EU Antitrust Fine Over Marketplace, Facebook Bundling

Jul 25, 2024

12:00 PM EDT, 07/25/2024 (MT Newswires) -- Meta Platforms ( META ) will soon receive its first European Union antitrust fine for integrating its Marketplace classified advertisements service to its Facebook social network, Reuters reported Thursday, citing people with direct knowledge of the matter. The fine could reach up to $13.4 billion, though actual penalties in EU are usually lower,...

Update: Pegasystems Shares Rise After Q2 Results Top Estimates

Jul 25, 2024

12:01 PM EDT, 07/25/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.) Pegasystems ( PEGA ) shares rose 13% in recent Thursday trading, a day after the company reported Q2 non-GAAP diluted earnings of $0.52 per share, up from $0.01 a year earlier. Analysts polled by Capital IQ expected $0.29. Revenue in the quarter ended...

Update: Teradyne Shares Fall After Q2 Results, Q3 Outlook

Jul 25, 2024

12:04 PM EDT, 07/25/2024 (MT Newswires) -- (Updates with latest stock move in the headline and first paragraph.) Teradyne ( TER ) shares fell almost 12% in recent Thursday trading after the company reported results for Q2 and provided guidance for Q3. The company reported Q2 non-GAAP earnings late Wednesday of $0.86 per diluted share, up from $0.79 per share...

Update: Viking Therapeutics Shares Jump After Q2 Loss Widens Less Than Projected

Jul 25, 2024

12:01 PM EDT, 07/25/2024 (MT Newswires) -- (Updates with the latest stock price movement in the headline and first paragraph.) Viking Therapeutics' ( VKTX ) shares were up nearly 38% in recent Thursday trading, a day after the company reported that its Q2 loss widened less than expected. The company reported a Q2 net loss late Wednesday of $0.20 per...